Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women

Article English OPEN
Ruiz-Sternberg, Ángela María; Moreira, Edson D.; Restrepo, Jaime A.; Lazcano-Ponce, Eduardo; Cabello, Robinson; Silva, Arnaldo; Andrade, Rosires; Revollo, Francisco; Uscanga, Santos; Victoria, Alejandro; Guevara, Ana María; Luna, Joaquín; Plata, Manuel; Dominguez, Claudia Nossa; Fedrizzi, Edison; Suarez, Eugenio; Reina, Julio C.; Ellison, Misoo C.; Moeller, Erin; Ritter, Michael; Shields, Christine; Cashat, Miguel; Perez, Gonzalo; Luxembourg, Alain;
(2017)
  • Publisher: Elsevier
  • Journal: volume 5,pages63-74issn: 2405-8521, eissn: 2405-8521
  • Publisher copyright policies & self-archiving
  • Related identifiers: doi: 10.1016/j.pvr.2017.12.004, pmc: PMC5887018
  • Subject: Gynecological Examination | PPI, per-protocol immunogenicity | Seroconversion | Major Clinical Study | mMU, milli-Merck units | Virus Antibody | Virus Dna | Human Papillomavirus Type 33 | Double Blind Procedure | Human Papillomavirus Type 31 | Vagina Smear | HPV, human papillomavirus | Persistent Infection | Female | WHO, World Health Organization | Vomiting | Cl, confidence interval | Dizziness | Uterine Cervix Dysplasia | Drug Safety | Adverse Event | Injection Site Pruritus | 9Vhpv | PCR, polymerase chain reaction | Cervical Cancer | Treatment Outcome | Article | Papillomavirus Infection | Human Papillomavirus Type 58 | Nausea | Antibody Response | Human Papillomavirus | Adolescent | Injection Site Erythema | Adult | qHPV, quadrivalent human papillomavirus | Male | Child | Vaccination | Uterine Cervix Cytology | Injection Site Swelling | Vaccine Immunogenicity | Injection Site Pain | Fever | AE, adverse event | Vulva Disease | 9vHPV, 9-valent human papillomavirus | Blood Analysis | HPV-9 cLIA, 9-valent competitive Luminex immunoassay | Antibody Blood Level | Human Papillomavirus Type 52 | PPE, per-protocol efficacy | Infectious and parasitic diseases | Papiloma | Hispanic | Priority Journal | Human | Vacuna contra papilomavirus | Wart Virus Vaccine | Disease Association | Randomized Controlled Trial | Drug Fatality | Human Papillomavirus Type 45 | Vaccine | SD, standard deviation | RC109-216 | Controlled Study | Vagina Disease | Neoplasias del cuello uterino | Drug Efficacy | Headache | GMT, geometric mean titer | CIN, cervical intraepithelial neoplasia

Background: A 9-valent human papillomavirus (HPV6/11/16/18/31/33/45/52/58; 9vHPV) vaccine was developed to expand coverage of the previously developed quadrivalent (HPV6/11/16/18; qHPV) vaccine. Methods: Efficacy, immunogenicity, and safety outcomes were assessed in Lat... View more
Share - Bookmark